From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

I'm still not buying the stock - or drinking the product - of Fever-tree

By Chris Bailey of Financial Orbit | Thursday 18 March 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I think I have tried a Fever-tree (FEVR) product once but I do not have the right drink preference to be a natural big fan.  Anyhow, I did not decide to chase the stock when I last wrote it up in April last year here which actually turned out to be a duff call, as it seems many investors seemed comfortable in paying a higher and higher multiple.  Well, funnily enough, I have never really found a forward 40 plus earnings multiple as an easy purchase.  

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 17:07:51